Profile
Founded in 2011 at the Hsinchu Biomedical Science Park, GWOXI has established the R&D center dedicated to developing cell therapy products that address unmet medical needs.
Establishing pharmaceutical-grade stem cell production platform, GWOXI has adopted its core technology Nigiro-Med® stem cell activation technology to develop multiple patents, while providing stem cell bank and cell therapy product testing services. Leveraging Nigiro-Med®, GWOXI has developed four stem cell medicines in clinical trial.
overseas
GWOXI delivers end-to-end stem cell technology services with international-standard quality. With a validated PIC/S GMP facility in the Hsinchu Biomedical Science Park, we ensure product safety, scalability, and consistency to advance the industrialization of regenerative medicine.
Our core values are Innovation Excellence and Responsibility. We hope one day our stem cell medicine can be a game changer to contribute to the medical field and help patients.Our goal is to keep expanding the cell therapy application and providing the new choice for patients with unmet medical needs.
- Beyond its exclusive technology platform, professional R&D team, and strong global partnerships, GWOXI continues to enhance its core technologies and integrated platforms. Leveraging robust research capabilities and pragmatic strategies, we are building a global presence and creating a differentiated advantage in the cell therapy industry. This approach reinforces GWOXI’s position as a leader in stem cell innovation.
- GWOXI closely tracks market dynamics and has established a strong strategic position in the cell therapy industry. We are dedicated to developing stem cell medicines that address unmet medical needs and target significant market opportunities, with four cell therapy products already in ongoing clinical trials. Furthermore, within the intensely competitive biotech sector, GWOXI adopts a dual-track strategy, advancing innovative technologies and providing comprehensive technical services to drive growth in both profitability and innovation.
- GWOXI’s most significant breakthrough in recent years has been mastering pharmaceutical-grade stem cell technologies. With the establishment of the Nigiro-Med® patented processes, we can now harness the broad potential of stem cell applications.
Press Releases
Press Releases-
26202509Press ReleasesGWOXI Stem Cell Secures Taiwan Invention Patent for Stem Cell-Derived Composition in Wound Healing -
09202509Press ReleasesGWOXI Stem Cell Expands Cross-Border Collaborations — Engaging Potential Partners in Thailand -
22202508Press ReleasesGWOXI Stem Cell Partners with Malaysia’s Cell 101 to Expand into the Asia-Pacific Regenerative Medicine Market